\n Data tracked by StockTitan Argus<\/a> on the day of publication. \n <\/p>\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n 10\/23\/2025 – 01:30 AM
\n
\n
<\/p>\n
Basel, 23 October 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY<\/a>) announced today that Nina Schwab-Hautzinger (1975) has been appointed Head of Group Communications and a member of the enlarged Corporate Executive Committee effective 1 February 2026.<\/p>\n Nina Schwab-Hautzinger rejoins Roche from her role at BASF as Head of Corporate Communications and Government Relations. During her previous thirteen year tenure at Roche, Nina Schwab-Hautzinger held various communications leadership roles such as Head of Corporate Brand & Communications at the Group level and Head of Communications & Public Affairs for Pharma in Germany.\u00a0 She has also led the healthcare practice in a strategic communications consultancy in Singapore.<\/p>\n Nina Schwab-Hautzinger studied at the University of Mannheim, Germany and the University of Waterloo, Canada. She received her doctorate from the University of Zurich, Switzerland, Department of Communication and Media Research.<\/p>\n Roche\u2019s CEO Thomas Schinecker: \u201cI am pleased to announce that Nina Schwab-Hautzinger will be returning to Roche as Head of Group Communications and will join Roche\u2019s executive leadership team. In today\u2019s rapidly evolving world, clear and impactful communication is a critical success factor both internally and externally for any company. Nina\u2019s extensive expertise, expansive network, and her experience across global, regional, and local contexts will be instrumental in advancing our long-term strategic ambitions. I would like to thank the current Head of Group Communications, Barbara Schaedler, for staying on longer to ensure a smooth hand-over.”\u00a0<\/p>\n About Roche For over 125 years, sustainability has been an integral part of Roche\u2019s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. <\/p>\n Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. <\/p>\n
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world\u2019s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.<\/p>\n
![\"\"](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/02\/1771048218_948_F-Hoffmann-La-Roche-Ltd.png\")